Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Publication
- Publication Type
- File Type
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Modulator Therapy For Cystic Fibrosis: An Exploration Of Current Research, Jessalyn Rombocos
Modulator Therapy For Cystic Fibrosis: An Exploration Of Current Research, Jessalyn Rombocos
Senior Honors Theses
Developing a drug therapy that addresses the root cause of cystic fibrosis (CF) by increasing CFTR protein levels has long been a research challenge. After genetic therapy failed because a suitable delivery system could not be found, researchers began searching for small organic molecules that could act as chaperones for CFTR. These molecules, known as modulators, allowed CFTR to be assembled correctly and function similarly to wild type CFTR. Since 2012, four modulator drugs have been developed, tested, and approved by the FDA. In October 2019, Trikafta was approved as the first triple-combination modulator drug and has completely revolutionized CF …
Sustainability And Outcomes Of A Standardized Aminoglycoside Induced Ototoxicity Monitoring Algorithm, Claire Elson, Christopher M. Oermann, Michelle Weltman, Ellen Meier
Sustainability And Outcomes Of A Standardized Aminoglycoside Induced Ototoxicity Monitoring Algorithm, Claire Elson, Christopher M. Oermann, Michelle Weltman, Ellen Meier
Posters
No abstract provided.
Improving Pneumococcal Polysaccharide Vaccination In Children With Cystic Fibrosis, Adam Van Mason, Wendy Estrellado-Cruz, Kristi Williams, Ellen Meier, Elizabeth Elson, Stephanie Duehlmeyer, Paula Capel, Jessica Banks, Christopher M. Oermann
Improving Pneumococcal Polysaccharide Vaccination In Children With Cystic Fibrosis, Adam Van Mason, Wendy Estrellado-Cruz, Kristi Williams, Ellen Meier, Elizabeth Elson, Stephanie Duehlmeyer, Paula Capel, Jessica Banks, Christopher M. Oermann
Posters
No abstract provided.
Cystic Fibrosis: Cftr, Complications, And Prospective Therapies, Rachel L. Rose
Cystic Fibrosis: Cftr, Complications, And Prospective Therapies, Rachel L. Rose
Chancellor’s Honors Program Projects
No abstract provided.
Lipotoxin F Of Pseudomonas Aeruginosa Is An Algu-Dependent And Alginate-Independent Outer Membrane Protein Involved In Resistance To Oxidative Stress And Adhesion To A549 Human Lung Epithelia, F. Damron, Jennifer Napper, M. Teter, Hongwei Yu
Lipotoxin F Of Pseudomonas Aeruginosa Is An Algu-Dependent And Alginate-Independent Outer Membrane Protein Involved In Resistance To Oxidative Stress And Adhesion To A549 Human Lung Epithelia, F. Damron, Jennifer Napper, M. Teter, Hongwei Yu
Hongwei Yu
Chronic lung infection with P. aeruginosa and excessive neutrophil-associated inflammation are major causes of morbidity and mortality in patients with cystic fibrosis (CF). Overproduction of an exopolysaccharide known as alginate leads to the formation of mucoid biofilms that are resistant to antibiotics and host defences. Alginate overproduction or mucoidy is controlled by a stress-related ECF sigma factor AlgU/T. Mutation in the anti-sigma factor MucA is a known mechanism for conversion to mucoidy. Recently, we showed that inactivation of a kinase (KinB) in nonmucoid strain PAO1 results in overproduction of alginate. Here, we report the initial characterization of lipotoxin F (LptF, …